← Leaderboards
Arun K Sharma
Texas A&M University Health Science Ctr
$2,620,326
Attributed
$4,429,671
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $541.5K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,429,671 · 7
By mechanism
R01$3,196,482 · 2
R21$784,914 · 2
R03$448,275 · 3
Top collaborators
- Chendil Damodaran6 shared
- Richard B Mailman3 shared
- David B. Stewart3 shared
Most similar at Texas A&M University Health Science Ctr
Same institution · by research overlap
- Chendil Damodaran$13,213,142
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseIn VivoToxic EffectDesignBasePropertyAnalogSignal TransductionOralTumor GrowthSeriesLeadMolecularMaximum Tolerated DoseBindingIn VitroGrowthMediatingStructure-Activity RelationshipResistanceBinding SitesPharmacokinetics And PharmacodynamicsBody WeightPhysiological
Grant awards (20)
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer$450,179
R01 · FY2025 · CA
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer$432,829
R01 · FY2024 · CA
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer$448,531
R01 · FY2023 · CA
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer$448,534
R01 · FY2022 · CA
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer$395,105
R01 · FY2021 · CA
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer$1
R01 · FY2021 · CA
In vivo agonist molecular probes for the dopamine D1 receptor$342,828
R01 · FY2020 · NS
A promising small molecule for pancreatic cancer therapy$164,641
R21 · FY2020 · CA · contact PI
In vivo agonist molecular probes for the dopamine D1 receptor$343,461
R01 · FY2019 · NS
A promising small molecule for pancreatic cancer therapy$198,064
R21 · FY2019 · CA · contact PI
In vivo agonist molecular probes for the dopamine D1 receptor$335,014
R01 · FY2018 · NS
Cationic Bolaamphiphiles (CAB) and Phosphorothioate Gapmers as Antisense Therapy for C. difficile$196,507
R21 · FY2018 · AI
Cationic Bolaamphiphiles (CAB) and Phosphorothioate Gapmers as Antisense Therapy for C. difficile$121,832
R21 · FY2017 · AI
Cationic Bolaamphiphiles (CAB) and Phosphorothioate Gapmers as Antisense Therapy for C. difficile$103,870
R21 · FY2017 · AI
A novel compound for colorectal cancer prevention$74,443
R03 · FY2015 · CA · contact PI
A novel compound for colorectal cancer prevention$74,521
R03 · FY2014 · CA · contact PI
Development of a novel agent for lung cancer prevention$71,053
R03 · FY2013 · CA · contact PI
Development of a novel agent for lung cancer prevention$75,588
R03 · FY2012 · CA · contact PI
ISC-4 as a Novel Lung Cancer Chemopreventive Agent$76,317
R03 · FY2010 · CA · contact PI
ISC-4 as a Novel Lung Cancer Chemopreventive Agent$76,353
R03 · FY2009 · CA · contact PI